Neither remdesivir NOR hydroxychloroquine lower the risk of respiratory failure in COVID-19 patients

A new study from Oslo University Hospital, in Norway, found that neither remdesivir nor hydroxychloroquine reduced respiratory failure or lowered inflammation in COVID-19 patients.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news